We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Deloitte has found a sharp decline in the returns on investment from top pharmaceutical companies, with returns at almost half of what they were in 2010